---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-027135"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:24:08.400416+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Brooklyn ImmunoTherapeutics CSO Kevin D'Amour resigns; effective date TBD

## Summary
- Dr. Kevin D'Amour, Chief Scientific Officer, submitted resignation notice on July 21, 2022.
- Effective date of resignation not yet determined by the Company and Dr. D'Amour.
- No successor or interim CSO announced in the filing.

## SEC filing metadata
- accession: 0001140361-22-027135
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036122027135/0001140361-22-027135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036122027135/brhc10040035_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-027135
- JSON: https://secwatch.observer/filing/0001140361-22-027135.json
- Plain text: https://secwatch.observer/filing/0001140361-22-027135.txt

## Key facts
- Executive change
  Dr. Kevin D'Amour resigned as Chief Scientific Officer at Ernexa Therapeutics Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), delivered his notice of resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122027135/0001140361-22-027135-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.